Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs

Applied Radiation and Isotopes

Volumn 85, Issue , 2014, Pages 28-33

  de Blois, Erik ^a   Chan, Ho Sze ^a   de Zanger, Rory ^a   Konijnenberg, Mark ^a   Breeman, Wouter A P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Ascorbic acid; Ethanol; Gentisic acid; Quenchers; Radiochemical purity; Somatostatin

Indexed keywords

LIQUID FORMULATIONS; QUENCHERS; RADIOCHEMICAL PURITY; RADIOLABELLING; SOMATOSTATIN;

ASCORBIC ACID;

ETHANOL;

ALCOHOL; ASCORBIC ACID; GENTISIC ACID; OCTREOTATE[3 TYROSINE TETRAXETAN] IN 111; OCTREOTATE[3 TYROSINE TETRAXETAN] LU 177; OCTREOTIDE[3 SODIUM IODIDE TETRAXETAN] IN 111; OCTREOTIDE[3 SODIUM IODIDE TETRAXETAN] LU 177; PENTETREOTIDE IN 111; PENTETREOTIDE LU 177; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOLYSIS;

ASCORBIC ACID; ETHANOL; GENTISIC ACID; QUENCHERS; RADIOCHEMICAL PURITY; SOMATOSTATIN;

ASCORBIC ACID; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUG STORAGE; ETHANOL; GENTISATES; HUMANS; INDIUM RADIOISOTOPES; LUTETIUM; RADIOISOTOPES; RADIOPHARMACEUTICALS; SOLUTIONS; SOMATOSTATIN;

EID: 84890809422     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2013.10.023     Document Type: Article

References (34)

1. Adamson A.R., Grahame-Smith D.G., Peart W.S. Pharmacological blockade of carcinoid flushing provoked by catecholamines and alcohol. Am. Heart J. 1971, 81:141-142.
2. 111In-DTPA-d-phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991, 49:1583-1591.
3. Bernard B.F., Krenning E., Breeman W.A., Visser T.J., Bakker W.H., Srinivasan A., de Jong M. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl. Med. Commun. 2000, 21:1079-1085.
4. 177Lu to a High Specific Activity 2006, Taylor & Francis Group, New York. first ed.
5. 177Lu, and 68Ga for peptide-receptor scintigraphy and peptide-receptor radionuclide therapy in preclinical and clinical applications. Monograph 2012, 16. (LESSON 5).
6. Breeman W.A., de Jong M., de Blois E., Bernard B.F., Konijnenberg M., Krenning E.P. Radiolabelling DOTA-peptides with 68Ga. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:478-485.
7. 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:917-920.
8. Breeman W.A., De Jong M.T., De Blois E., Bernard B.F., De Jong M., Krenning E.P. Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+. Nucl. Med. Biol. 2004, 31:821-824.
9. Breeman W.A., Froberg A.C., de Blois E., van Gameren A., Melis M., de Jong M., Maina T., Nock B.A., Erion J.L., Macke H.R., Krenning E.P. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. Nucl. Med. Biol. 2008, 35:839-849.
10. Breeman W.A., Kwekkeboom D.J., de Blois E., de Jong M., Visser T.J., Krenning E.P. Radiolabelled regulatory peptides for imaging and therapy. Anti-Cancer Agents Med. Chem. 2007, 7:345-357.
11. 177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:312-315.
12. Breeman W.A.P., Melis M.L., de Blois E., Mueller C., De Jong M., Krenning E.P. Effects of quenchers on radiochemical purity and biological activity of [In-111-DOTA(0), Tyr(3)]-octreotate. Eur. J. Nucl. Med. Mol. Imaging 2007, 34(Supplement: 2):S337. (S337).
13. Chavatte K., Mertens J., Terriere D., Van Den Winkel P. Parameters ruling optimization of radiolabelling of polyamino polycarboxylated functionalized peptide derivatives: a case study report. Nucl. Med. Biol. 2001, 28:745-749.
14. 177Lu]Lu-AMBA, a systemic radiotherapeutic agent for gastrin releasing peptide receptor positive tumors. Appl. Radiat. Isot. 2008, 66:497-505.
15. de Blois E., Chan H.S., Konijnenberg M., de Zanger R., Breeman W.A. Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC. Curr. Top. Med. Chem. 2012, 12:2677-2685.
16. 2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides. Appl. Radiat. Isot. 2011, 69:308-315.
17. 177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 2001, 92:628-633.
18. 111In-labelled bombesin analogues for molecular imaging of prostate tumours. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1228-1238.
19. Erion, J.L., 2008. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide. Publication no. WO2008009444. International application no. PCT/EP2007/006404.
20. Filice A., Fraternali A., Frasoldati A., Asti M., Grassi E., Massi L., Sollini M., Froio A., Erba P.A., Versari A. Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: a single centre experience. J. Oncol. 2012, 2012:320198.
21. Fukumura T., Nakao R., Yamaguchi M., Suzuki K. Stability of C-11-labeled PET radiopharmaceuticals. Appl. Radiat. Isot. 2004, 61:1279-1287.
22. Garrison W.M. Reaction-mechanisms in the radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 1987, 87:381-398.
23. Hofland L.J., Breeman W.A., Krenning E.P., de Jong M., Waaijers M., van Koetsveld P.M., Macke H.R., Lamberts S.W. Internalization of [DOTA degrees,125I-Tyr3]octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery. Proc. Assoc. Am. Phys. 1999, 111:63-69.
24. Jay-Gerin J.P., Ferradini C. A new estimate of the (OH)-O-center dot radical yield at early times in the radiolysis of liquid water. Chem. Phys. Lett. 2000, 317:388-391.
25. Jonah C.D. A short history of the radiation chemistry of water. Radiat. Res. 1995, 144:141-147.
26. Liu S., Cheung E., Rajopadhye M., Williams N.E., Overoye K.L., Edwards D.S. Isomerism and solution dynamics of (90)Y-labeled DTPA-biomolecule conjugates. Bioconjugate Chem. 2001, 12:84-91.
27. Liu S., Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjugate Chem. 2001, 12:7-34.
28. Liu S., Ellars C.E., Edwards D.S. Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals. Bioconjugate Chem. 2003, 14:1052-1056.
29. Long R.G., Peters J.R., Bloom S.R., Brown M.R., Vale W., Rivier J.E., Grahame-Smith D.G. Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut 1981, 22:549-553.
30. Petrik M., Knetsch P.A., Knopp R., Imperato G., Ocak M., von Guggenberg E., Haubner R., Silbernagl R., Decristoforo C. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl. Med. Commun. 2011, 32:887-895.
31. Schuessler H. Effect of ethanol on radiolysis of ribonuclease. Int. J. Radiat. Biol. 1975, 27:171-180.
32. Serdons K., Verbruggen A., Bormans G. The presence of ethanol in radiopharmaceutical injections. J. Nucl. Med. 2008, 49:2071.
33. Stabin M.G., Konijnenberg M.W. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J. Nucl. Med. 2000, 41:149-160.
34. 2O->H-2+(center dot)OHin the radiolysis of water at high temperatures. Radiat. Phys. Chem. 2005, 74:210-219.